A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPI-1005 in Adults Receiving a Cochlear Implant
Latest Information Update: 27 May 2024
At a glance
- Drugs Ebselen (Primary)
- Indications Sensorineural hearing loss
- Focus Adverse reactions
- Sponsors Sound Pharmaceuticals
Most Recent Events
- 20 May 2024 According to a Sound Pharmaceuticals media release, the company has received FDA notification that its Investigational New Drug Application (IND) may proceed involving SPI-1005 treatment and cochlear implantation (CI).
- 03 Apr 2024 New trial record